Category: Asia Pacific Region

Posted on

Ping An Digital Bank Embarks on a New Journey

Source: Media Outreach

“Always with You, Always Ahead,” From banking services to life protection planning, professionally supports your journey with peace of mind

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Ping An Digital Bank (International) Limited (“Ping An Digital Bank” or “PingAnDB”) unveils its new branding today. As one of the integrated financial platforms in Hong Kong under Ping An Insurance (Group) Company of China, Ltd. (“Ping An”; SEHK: 2318; SSE: 601318), Ping An Digital Bank leverages the Group’s technology integrated strength to embark on an exciting new chapter.

With a core commitment to enhancing customer experience, Ping An Digital Bank adheres to its vision of “Always with You, Always Ahead.” Harnessing innovative technology, the Bank redefines the digital banking journey, making it simpler for customers to manage their deposits, investments, and insurance – all from a single account from their mobile device. Striving to anticipate customer needs and go the extra mile, Ping An Digital Bank empowers customers to take smarter steps towards financial growth and accumulate wealth steadily over time, without the burden of complex procedures or heavy research.

Mr. Ronald Iu, Chief Executive of Ping An Digital Bank, said, “We are delighted to unveil a brand new Ping An Digital Bank. This better reflects our deep connection with Ping An Group, integrating our signature ‘insurance DNA’ directly into our banking services and further reinforcing our role as an integrated financial platform in Hong Kong. Moving forward, Ping An Digital Bank will continue to develop both retail and business banking. Our team is dedicated to our brand vision of ‘Always with You, Always Ahead’ as our brand image transforms – building trust as the foundation, and simplicity as our priority. From banking to life protection planning, our professional team stands ready to support our clients throughout every stage of their financial journey.”

Retail Banking: User-Centric at the Core
One Account for Deposits, Investments & Insurance
Since joining Lufax in 2024, Ping An Digital Bank has accelerated the development of its retail banking offerings, launching online and offline insurance, as well as wealth services. With one single account that integrates deposits, foreign exchange, cross-border remittances, wealth and insurance, customers can now enjoy truly one-stop financial experience. As of 15 March 2026, total retail banking deposits have surpassed HK$ 12 billion.

With user-friendliness at the heart of its design, Ping An Digital Bank’s retail banking services aim to minimise redundant steps and simplify money management. The latest dual-advantage wealth solution marries the experience of agility of a brokerage with the security of a bank, allowing customers to invest in Hong Kong stocks, U.S. stocks, funds, and money market funds directly from their savings accounts with no extra transfers required, enabling customers to SWITCH flexibly between investment and deposit services.

Powered by Ping An’s robust insurance pedigree, Ping An Digital Bank leads the market as Hong Kong’s first digital bank to provide a full spectrum of online and offline insurance services. For unrivalled efficiency, customers can purchase general insurance products, including motor insurance, travel insurance, and home insurance products, online within minutes. For client-centric experience with human touch, the Bank’s offline platform delivers an extensive range of life protection and savings plans, tailored to each client’s needs.

Business Banking: A Pillar of Support for Trade Enterprises
Driving Breakthroughs with Data & Technology
As a leading digital bank for SMEs in Hong Kong, Ping An Digital Bank plays a pivotal role in supporting the city’s trading enterprises. By harnessing advanced technology and business data, the Bank is striving to help unleash the full potential of Hong Kong’s digital economy while backing the HKSAR Government’s vision for smart city development. Through the integration of trade, logistics, and financial data, Ping An Digital Bank is revolutionising the credit approval process to deliver quicker and more flexible assessments, empowering a broader range of businesses to seize new opportunities.

From account opening and foreign exchange to cross-border remittances and financing, Ping An Digital Bank stands as a key pillar of support for trading enterprises, providing an integrated business banking suite that meets the practical needs of companies in both daily operations and international expansion. Leveraging innovative data models, the Bank empowers trading SMEs to advance their operations and thrive, and thus becoming a dedicated and trusted partner for business growth.

Looking ahead, Ping An Digital Bank will continue to put customer convenience at the heart of its services, striving to help both individuals and businesses to save time, effort and cost. The Bank is dedicated to setting new benchmarks for digital banking, while reinforcing its position as a key pillar within Ping An Group’s integrated financial platform in Hong Kong.

Investment involves risk. The price of investments fluctuates, sometimes dramatically. The price of investments may move up or down, and may become valueless. There is an inherent risk that losses may be incurred rather than profit made as a result of buying and selling investment products. Foreign investments carry additional risks not generally associated with the domestic market. You should carefully consider whether any investment products or services mentioned herein are appropriate for you in view of your investment experience, objectives, financial resources and circumstances.

Hashtag: #PingAnDigitalBank #平安數字銀行

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/27/ping-an-digital-bank-embarks-on-a-new-journey/

Posted on

WRISE Group Partners with China Asset Management (Hong Kong) to Offer Exclusive Access to Asia Bond Fund high dividend yield share class in Hong Kong Debut

Source: Media Outreach

  1. WRISE Prestige is the first firm in Hong Kong to offer the ChinaAMC Select Asia Bond Fund (Income Share Class), marking a milestone partnership that reinforces its standing as a leading wealth management firm.
  2. The Fund’s Income share class * offers a target dividend yield of approximately 9%, combining strong historical performance with flexible, benchmark-unconstrained allocation to meet growing demand for income-generating solutions in Asia.
  3. The partnership underscores WRISE’s commitment to expanding its curated suite of institutional-grade investment solutions for sophisticated investors across the region.

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – WRISE Group (“WRISE“), one of Asia’s fastest-growing independent wealth management firm, announced that WRISE Prestige, has established a strategic partnership with China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)“), one of the region’s most established asset managers. Through this collaboration, WRISE Prestige will serve as the first launch partner in Hong Kong with a period of exclusive access to the ChinaAMC Select Asia Bond Fund (INC share class), offering clients a compelling fixed income solution designed for yield and diversification. To mark the partnership and the launch of the exclusive share class, WRISE Prestige and ChinaAMC (HK) co-hosted an event yesterday to formally announce the collaboration and introduce the investment strategy behind the ChinaAMC Select Asia Bond Fund to invited guests and clients.

The ChinaAMC Select Asia Bond Fund adopts a flexible, benchmark-unconstrained investment approach, allowing the fund manager to capitalise on opportunities across Asian credit markets dynamically. By focusing on fundamentally sound issuers, with a particular emphasis on China and the broader Asian region, the Fund seeks to deliver attractive risk-adjusted returns. Its strong historical track record underscoring the robustness of its investment process.

Recent geopolitical tensions have triggered significant volatility across global financial markets, making diversified, income-oriented strategies that can navigate geopolitical uncertainty paramount for sophisticated investors seeking portfolio resilience. With a target dividend yield of approximately 9%*, the Fund’s Income share class is positioned to address the increasing demand among Asian investors for stable and sufficient cash flow solutions. This income-focused strategy complements the broader portfolio needs of high-net-worth individuals seeking resilience and yield beyond traditional asset classes.

Henry Shin, Chief Executive Officer of WRISE Prestige, said: “We are delighted to partner with ChinaAMC to bring the ChinaAMC Select Asia Bond Fund (Income Share Class) to our clients as an exclusive launch in Hong Kong. In today’s volatile geopolitical landscape, investors require solutions that can adapt to changing conditions while delivering consistent income. The ChinaAMC Select Asia Bond Fund embodies this approach, offering flexible mandate and strong yield potential that make it a valuable addition to our curated platform.”

Barney Gao, Head of Strategic Client Development at China Asset Management (Hong Kong), said, “We are pleased to collaborate with WRISE Prestige to introduce the ChinaAMC Select Asia Bond Fund (Income Share Class) to investors in Hong Kong. This partnership reflects our commitment to delivering innovative and performance-driven investment solutions to a broader audience. With its focus on Asian bond markets and a flexible investment strategy, the Fund is well-suited to meet the income and diversification needs of investors in the region.”

This partnership highlights WRISE’s ongoing strategy to broaden access to best-in-class asset managers and deliver tailored investment solutions that address the complex and evolving needs of private wealth clients across Asia.

Important Information

This document is issued by WRISE Prestige Securities Limited (CE No. BSJ229). This document is for information purposes only and does not constitute and should not be construed as an offer, solicitation, recommendation or advice to buy or sell any investment product, nor should it be regarded as investment research.

Investment involves risks. The value of investments may go down as well as up and investors may not get back the principal invested. Past performance is not indicative of future performance.

The ChinaAMC Select Asia Bond Fund is authorized by the Securities and Futures Commission (“SFC”) in Hong Kong. SFC authorization is not a recommendation or endorsement of the Fund nor does it guarantee the commercial merits of the Fund or its performance. It does not mean the Fund is suitable for all investors.

Distributions (if any) are not guaranteed. Distribution rates are not indicative of the Fund’s return. The Fund may pay distributions out of income and/or capital (or effectively out of capital), which may result in an immediate reduction of the Fund’s net asset value.

This document has not been reviewed by the SFC.

* The Manager may at its discretion pay dividend out of capital or effectively out of the capital of the Funds. Payment of dividends out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any such capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Unit.

Hashtag: #WRISE

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/27/wrise-group-partners-with-china-asset-management-hong-kong-to-offer-exclusive-access-to-asia-bond-fund-high-dividend-yield-share-class-in-hong-kong-debut/

Posted on

EarBalance Rebrands to Reflect Integrated Hearing and Balance Care, Introduces Singapore’s First FDA-Approved OTC Hearing Aid Solution, and Announces Major Community Hearing Initiative

Source: Media Outreach

SINGAPORE – Media OutReach Newswire – 26 March 2026 – EarBalance Pte. Ltd., a well-established audiology clinic in Singapore, has unveiled a series of significant developments that underscore its commitment to redefining hearing and balance care. Formerly known as Sound Balance, the clinic has officially rebranded to EarBalance to better reflect its expanded scope of services and its collaborative approach with Ear, Nose and Throat (ENT) specialists. Alongside this transformation, the clinic is preparing to launch Singapore’s first FDA- and Health Sciences Authority (HSA)-approved over-the-counter (OTC) hearing aid solution, while also spearheading a major community hearing awareness initiative set to take place in June 2026.

Dr. Kenneth Chua, Senior Principal Audiologist, EarBalance Pte. Ltd.

These developments position EarBalance at the forefront of a shifting audiology landscape, one that increasingly prioritises accessibility, education, and holistic patient care.

A Strategic Rebrand to Reflect Broader Clinical Collaboration
The transition from Sound Balance to EarBalance Pte. Ltd. marks more than a change in name. It signals a strategic evolution in the clinic’s identity and clinical philosophy. While the former name emphasised audiology and sound perception, the new brand encompasses a more comprehensive understanding of ear health, thus integrating both hearing and balance functions.

“Our ears are not just for hearing. Very often, we think about our five senses, which include hearing. The sixth sense, which is our balance, is often forgotten,” said Dr Kenneth Chua, Senior Principal Audiologist at EarBalance Pte. Ltd. Dr Chua also noted that the rebrand reflects the clinic’s commitment to addressing both aspects of ear health through a collaborative, multidisciplinary model that includes close partnerships with ENT specialists.

EarBalance has established strategic collaborations with several ENT groups, including ASCENT ENT Group, enabling a more seamless patient journey from diagnosis to treatment. This integrated care model ensures that patients presenting with hearing loss, dizziness, or vertigo receive comprehensive evaluation and management under one coordinated framework.

Introducing Singapore’s First FDA- and HSA-Approved OTC Hearing Aid
In April 2026, EarBalance will launch the CERETONE OTC hearing aid, developed by a Canadian company in partnership with ENTRUST. This marks a significant milestone in Singapore’s hearing care sector, as it represents the first OTC hearing aid approved by both the U.S. Food and Drug Administration (FDA) and Singapore’s Health Sciences Authority (HSA).

Designed for individuals with mild hearing loss, CERETONE offers a cost-effective and accessible alternative to traditional prescription hearing aids. The device allows users to manage their hearing needs more independently, making it particularly suitable for those who may not yet be ready to commit to medical-grade solutions.

“This hearing aid is ideal for those with mild hearing loss and who may not be ready for medical-grade prescription hearing aids. We plan to continue expanding the inventory of innovative technological solutions to help people ‘hear better and live better,’” noted Dr Chua.

The CERETONE device combines a user-friendly design with specialised sound processing technology, enabling wearers to adjust settings according to their listening environment. This innovation aligns with EarBalance’s broader mission to “help people hear better and live better” by expanding its portfolio of technological solutions.

Addressing Industry Misconceptions Through Education
EarBalance’s latest initiatives also reflect its stance on a persistent challenge within the hearing care industry: The perception of hearing aids as consumer commodities rather than medical interventions.

“The hearing industry has long been shaped by transactional relationships, where hearing aids are viewed as products to be sold,” added Dr Chua. “However, as healthcare professionals, our role is not to sell devices, but to guide patients in making informed decisions about their hearing health.”

This philosophy is particularly important in light of growing evidence linking untreated hearing loss to broader health risks. Studies have shown that up to 8 per cent of modifiable risk factors for dementia may be attributed to hearing loss. Early detection and intervention are therefore critical not only for communication but also for long-term cognitive health.

EarBalance places strong emphasis on patient education, ensuring that individuals understand the implications of hearing loss and the range of available interventions. By shifting the focus from sales to informed care, the clinic aims to foster trust and empower patients to take ownership of their hearing health.

Community Hearing Awareness Initiative to Launch in June 2026
In line with its commitment to public health, EarBalance will co-organise a large-scale community hearing awareness and education event in June 2026. The initiative is a collaboration between ASCENT ENT Group, EarBalance Audiology Clinic, and Thomson Medical Centre, with support from WS Audiology under the WSA (Wonderful Sound for All) foundation.

The event aims to address a critical gap in public awareness regarding hearing health, particularly the importance of early intervention. It will offer a comprehensive programme that includes hearing screenings, educational sessions, and professional consultations.

“Untreated hearing loss can lead to social isolation, reduced communication ability, and even cognitive decline,” Dr. Chua explained. “Through this initiative, we hope to encourage individuals to take proactive steps in managing their hearing health.”

The programme is expected to screen approximately 100 participants, with an estimated 40 to 50 individuals identified as needing hearing amplification support. For those facing financial barriers, refurbished hearing aids will be provided through CSR contributions, ensuring that care is accessible to underserved segments of the community.

A Holistic Approach to Hearing Rehabilitation
Beyond screening and education, the June initiative will provide referral pathways for continued care, connecting participants with ENT specialists and audiologists for further evaluation and treatment. This integrated approach ensures that individuals identified with hearing loss receive not only a diagnosis but also actionable solutions.

The programme will also feature hearing health education sessions, designed to demystify common misconceptions and equip participants with practical knowledge about ear care. Topics will include the impact of hearing loss on overall well-being, the benefits of early intervention, and the range of available treatment options.

Media coverage and community engagement will play a key role in amplifying the initiative’s impact. WS Audiology, as a CSR partner, will be recognised through branding on programme materials, event displays, and media campaigns.

Sustainability Through Hearing Aid Upcycling
EarBalance is also exploring sustainable practices within the hearing care space, particularly through the upcycling of hearing aids. Recognising that some patients may discontinue use of their devices, the clinic is considering programmes to refurbish and redistribute these aids to individuals in need.

“This initiative addresses two important issues, which are reducing electronic waste and improving access to hearing care,” said Dr Chua. “There are many individuals who could benefit from hearing aids but are unable to afford them. At the same time, there are devices that go unused. Bridging this gap is both a social and environmental responsibility.”

The proposed upcycling programme aligns with EarBalance’s broader vision of responsible healthcare, where innovation is balanced with sustainability and community impact.

Expanding the Scope of Ear Health: Hearing and Balance
A defining feature of EarBalance’s clinical approach is its focus on both hearing and balance, which is an often-overlooked aspect of ear health. While hearing loss is widely recognised, balance disorders such as dizziness and vertigo are frequently misunderstood or underdiagnosed.

“Our ears are not just for hearing,” Dr Chua emphasised. “The vestibular system, located in the inner ear, plays a crucial role in maintaining balance. When this system is disrupted, patients may experience dizziness, vertigo, or instability, which can significantly affect their quality of life.”

EarBalance provides specialised assessment and rehabilitation for balance disorders, offering patients a comprehensive solution that addresses both auditory and vestibular health. This dual focus sets the clinic apart in Singapore’s audiology landscape, where balance care is often treated as a separate discipline.

Looking Ahead: Building a Future of Integrated Care
As EarBalance continues to expand, it is exploring opportunities to further integrate hearing and balance services within clinical settings, including potential collaborations with Thomson Medical Centre. These efforts aim to create a seamless continuum of care for both adult and paediatric populations.

The clinic’s long-term vision includes the development of community-based programmes that extend beyond one-off initiatives, fostering sustained engagement and awareness around hearing health.

“Our goal is to build a healthcare ecosystem where hearing and balance care are accessible, integrated, and patient-centred,” said Dr Chua. “By combining clinical expertise, technological innovation, and community outreach, we hope to make a meaningful difference in people’s lives.”

Home

Hashtag: #EarBalance

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/earbalance-rebrands-to-reflect-integrated-hearing-and-balance-care-introduces-singapores-first-fda-approved-otc-hearing-aid-solution-and-announces-major-community-hearing-initiative/

Posted on

Nonstop in 11 Hours to the “City of Pandas”: Chengdu Launches Direct Flights to Brussels

Source: Media Outreach

CHENGDU, CHINA – Media OutReach Newswire – 26 March 2026 – Air China launched a direct passenger flight from Chengdu to Brussels, the capital of Belgium, with service starting March 26. This marks Chengdu’s 12th regular direct passenger route to Europe. The inaugural flight recorded a load factor of 95%, with the return leg reaching 85%, underscoring strong market demand.

Chengdu Tianfu International Airport

According to Air China’s Southwest Branch, the Chengdu (Tianfu International Airport)-Brussels route offers three round trips per week on the Airbus A330-300, with flights scheduled on Tuesdays, Thursdays, and Sundays. Previously, Chengdu had already opened a dedicated all-cargo route to Brussels. The launch of the passenger service now establishes a dual-track system for both passenger and freight transport.

Before the route’s launch, travelers from Chengdu to Brussels typically required a transfer, with the whole journey taking more than 17 hours. The new direct service cuts travel time to under 11 hours, creating a faster and more convenient aerial corridor for economic and trade cooperation, cultural exchange, and people-to-people connectivity between China and Belgium.

This route also represents Chengdu’s first newly launched intercontinental passenger service of the year. To date, the city operates 19 intercontinental passenger routes, including 12 connecting major European cities such as Frankfurt, London, Paris, and Brussels, with nearly 40 weekly flights. Chengdu’s regular international and regional direct routes have now clocked up 85, markedly boosting its global connectivity.

The ever-expanding international flight network has further stimulated inbound tourism. In 2025, Chengdu received 2.38 million inbound tourists, a year-on-year increase of 44.3%, signaling a strong recovery of the inbound tourism market. During the recent 2026 Spring Festival, the city welcomed 77,000 inbound tourists, up 47.2% year on year, with a growing number of international travelers choosing Chengdu as their top destination for experiencing China.

As noted by The Times in its feature on 12 of the Best Places to Visit in China: “Home of the Chengdu Research Base of Giant Panda Breeding, this city has become a popular stop on many China tours. Foodies will relish their visit—it’s one of the original UNESCO cities of gastronomy, so you’ll find the best of Sichuan cuisine here. Highlights include spicy hotpot, mapo tofu, and the myriad street foods you’ll find outside Chengdu’s many temples. It’s also the departure point for tours to the national parks of Jiuzhai Valley and Huanglong, and the autonomous regions around Sichuan.”

To enhance the travel experience of international passengers, Chengdu has introduced a package of measures covering tax refunds upon payment, language services, smart navigation, and promotional incentives, all aimed at improving convenience and adding to the appeal of inbound tourism. Policies such as instant tax refunds, direct payments via overseas e-wallets, and over 600 tax refund stores have largely facilitated travel for international tourists.

In 2025, Chengdu had more than 6,000 taxi drivers trained in English, and the scenic area Xiling Snow Mountain rolled out an international booking platform supporting real-time translation in 24 languages and transactions in 29 currencies, with multilingual AI translation screens installed across major tourist attractions and transportation hubs in Chengdu.

Meanwhile, Jinli Street—once named by CNN as one of the world’s most beautiful streets—officially introduced the “Open Chengdu” cultural tourism base on February 6. The base features a professional English-language service team, more than 300 bilingual signs, and over 10 bilingual self-service ticketing machines supporting multiple ID types. Across more than 50 locations in Jinli, from museum gift shops to street vendors, international credit cards such as VISA are widely accepted.

In addition, Chengdu Eastern New Area, where Chengdu Tianfu International Airport is located, offers international transit passengers subsidies of up to 400 yuan per person, including 200 for hotel stays, 100 for consumption vouchers, and 100 for railway tickets.

Hashtag: #ChengduInformationOffice

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/nonstop-in-11-hours-to-the-city-of-pandas-chengdu-launches-direct-flights-to-brussels/

Posted on

XTransfer’s CSO Joins Roundtable Discussion in Rwanda

Source: Media Outreach

KIGALI, RWANDA – Media OutReach Newswire – 26 March 2026 – XTransfer, world’s leading B2B cross-border financial platform, was honoured to have its Chief Strategy Officer, Neil Ni, participate in the Remittances Roundtable: Policy and Partnerships Shaping the Next Generation of Cross-Border Flows at the Inclusive FinTech Forum 2026 in Rwanda, underscoring the company’s commitment to advancing faster, cheaper, and more transparent cross-border flows across Africa, especially for SMEs engaged in international trade.

XTransfer’s CSO, Neil Ni, speaks at the Remittances Roundtable at the Inclusive FinTech Forum 2026 in Rwanda.

During the session, Neil joined a roundtable featuring Bernard Rwisumbura Nsengiyumva of the National Bank of Rwanda, Dr Francis Lwanga of Zambia Electronic Clearing House Limited, Owureku Asare of the Bank of Ghana, Mike Truter of Swift, and other distinguished guests, moderated by Luca Antonio Ricci of the International Monetary Fund. The panellists explored what will practically move remittances and cross-border flows forward in 2026–2027, including interoperability, corridor liquidity and FX constraints, and proportionate compliance.

One theme that resonated strongly is that policy is starting to catch up with market needs. A timely example is the new cross-border payment access initiative by the central banks of Kenya and Rwanda (announced 11 March 2026), which introduces mutual recognition and a “fast-track” pathway for licensed payment providers operating between the two countries. Neil noted that reducing duplicative licensing steps, aligning core compliance expectations, and improving supervisory coordination can shorten expansion timelines, lower administrative costs, and ultimately support more reliable and affordable cross-border payments.

“As we look to the next phase of growth, what matters is not only innovation in rails, but alignment in rules and execution,” Neil said. “Interoperability, proportionate compliance, and corridor liquidity are levers that can make cross-border flows meaningfully faster, cheaper, and more transparent without compromising trust.”

Drawing on XTransfer’s experience supporting SMEs in global trade, Neil shared that a practical roadmap includes building on interoperable infrastructure, implementing robust and scalable compliance, and partnering with regulators and local ecosystems to strengthen transparency and unlock corridor liquidity. He added that this is a key reason XTransfer is building X-Net, the industry’s first Unified Global B2B Trade Settlement Network and Risk Control Platform, to connect ecosystem partners and support safer, more standardised information flows for cross-border trade and payments.

https://www.xtransfer.com
https://www.linkedin.com/company/xtransfer.cn
https://x.com/xtransferglobal
https://www.facebook.com/XTransferGlobal/
https://www.instagram.com/xtransfer.global

Hashtag: #XTransfer #Crossborder #Payment #SMEs #Africa

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/xtransfers-cso-joins-roundtable-discussion-in-rwanda/

Posted on

Ayako Rokkaku Unveils ‘THE ISLAND – ONIGASHIMA’ at LANDMARK: A Monumental Artistic Odyssey in Central

Source: Media Outreach

A Grand Scale Hong Kong Solo Debut Transforms the Atrium into a Tactile Art Experience

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Today, LANDMARK proudly launches a new experience in its Art LANDMARK initiative with the unveiling of ‘THE ISLAND – ONIGASHIMA’, an ambitious installation by globally acclaimed artist Ayako Rokkaku — marking her most monumental and immersive art installation to date, in collaboration with GALLERY TARGET. From now until 17 April, LANDMARK Atrium is transformed into a vivid, tactile art experience — an unmissable fixture on Hong Kong’s cultural calendar – inviting visitors on a journey where imagination takes tangible form.

‘THE ISLAND – ONIGASHIMA’ marks Ayako Rokkaku’s highly anticipated Hong Kong solo debut and her largest installation worldwide within a commercial space — a reflection of LANDMARK’s commitment to bringing world-class artistic experiences to Central. Celebrated for her energetic, finger-painted works that have garnered immense popularity and praise across Asia, Rokkaku is one of the most sought-after voices in contemporary art, her canvases brimming with vibrant narratives and childlike wonder.

Step Inside ‘THE ISLAND– ONIGASHIMA’: An Interactive Dreamscape

Inspired by the mythical ‘Onigashima’ from Japanese folklore, Ayako Rokkaku thoughtfully selected this theme upon recognising the shared island geography of both Hong Kong and Japan. The artist’s vision further integrates Momotaro’s legendary ‘half-human, half-oni’ persona, which subtly symbolises the delicate boundary between dreams and reality. This fantastical quality inspired Rokkaku to infuse the art installation with a blend of childlike wonder and mystery, thereby blurring the lines between the artist and the audience.

Crafted with soft forms and inviting fabrics, ‘THE ISLAND – ONIGASHIMA’ is designed not just to be observed, but to be experienced. Rising to an impressive 6 metres, the sculpture creates a sprawling organic topography within the Atrium, which has been curated with a museum-like approach to invite interaction. Visitors are encouraged to touch, feel, and even repose upon its rich textures, transforming passive viewing into active engagement, allowing them to create their own journey without a prescribed path. Imagine stepping into a colossal, living artwork of soft forms where every interaction becomes a part of its story. Within the Atrium, the artwork encompasses a captivating tunnel housing 12 wooden sculptures for intimate viewing and beautifully surrounded by 11 additional paintings.

Ayako Rokkaku presented a special performance to mark the opening of ‘THE ISLAND – ONIGASHIMA’ by painting live at the installation. Witnessing her uninhibited gestures, layering vibrant pigments directly with her hands, offered a rare glimpse into the spontaneous creation of her iconic figures and landscapes. The session underscores her philosophy of direct artistic expression and the intimate connection between artist and creation. Later in the day, a cocktail party was hosted to celebrate the opening of the installation and featured dignitaries from around the region, including renowned Thai actor and singer Bright.

As a self-taught artist whose distinctive style emerged in 2006, Rokkaku blends manga influences with abstract and emotive colour fields that are often born spontaneously, without preparatory sketches, reflecting a raw and unmediated artistic impulse. Her signature motif — stylised wide-eyed girls surrounded by vibrant, multicoloured landscapes — has garnered global recognition, including the prestigious Illustration Prize at Takashi Murakami’s Geisai art fair. This collaboration is a further expression of LANDMARK’s ambition to bring the world’s most celebrated creative talents to Central, creating cultural experiences found nowhere else in Hong Kong.

Redefining Luxury Through Art: An Immersive Cultural Landmark

“Ayako Rokkaku’s ‘THE ISLAND – ONIGASHIMA’ represents everything we believe a great experience should be — immersive, surprising, and something that stays with you,” said Mr. Alexander Li, Director and Head of Retail, Hong Kong & Macau, Hongkong Land Limited. “That she chose LANDMARK for this reflects our simple goal: to deliver experiences that are best-in-class and uniquely Central. That is the spirit of our ongoing Tomorrow’s CENTRAL transformation, and it is what ‘Experience is Central’ means to us.”

Exclusive Engagement and Collectibles: Extending the Artistic Journey

Beyond the Atrium, BELOWGROUND hosts a dedicated pop-up where visitors can acquire a piece of Rokkaku’s distinctive universe. This curated space features a collection of 9 original artworks and exclusive limited editions, including 1 print in an edition of 50 and 1 bronze sculpture in an edition of 3, alongside a range of bespoke merchandise. Visitors can choose from a range of limited-edition tote bags, apparel, books, scarves, and a unique lamp collaboration with AllRightsReserved. This offers visitors the opportunity to take a souvenir home from ‘THE ISLAND – ONIGASHIMA’ and deepen their connection with Ayako Rokkaku’s unique artistic world.

For a holistic experience, visitors who begin their journey at BELOWGROUND are invited to explore the main installation in the Atrium for a different, interactive angle of ‘THE ISLAND – ONIGASHIMA‘.Adding to the immersive experience, MTR will launch a special digital Octopus card featuring the exhibition’s key visual, allowing the public to carry a piece of this art journey with them. Ayako Rokkaku will host an exclusive book signing event on March 24th at 6 PM. This special occasion offers visitors a unique opportunity to meet the renowned artist in person and acquire her latest publication, ‘Close To Your Treasure,’ directly on-site, complete with a personalized autograph. Further opportunities to engage with the artist through potential talks or panels will be announced shortly.

Hashtag: #LANDMARKHK

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/ayako-rokkaku-unveils-the-island-onigashima-at-landmark-a-monumental-artistic-odyssey-in-central/

Posted on

Bertelsmann Stiftung BTI Survey 2026: More Autocracies Worldwide – But Democratic Resistance Is Growing

Source: Media Outreach

Democracy is on the defensive. This is shown by the Bertelsmann Stiftung’s Transformation Index 2026 (BTI). The BTI was first surveyed twenty years ago, when democracies were still in the majority. Today, 56 percent of the 137 countries surveyed by the BTI are ruled autocratically. However, this rarely leads to better governance. Autocracies are more susceptible to corruption, less capable of shaping the future, and less consensus-oriented. However, examples such as Poland and Brazil show that social resistance and political competition can pave the way back to democracy.

GÜTERSLOH, GERMANY – Newsaktuell – 26 March 2026 – A majority of 77 of the 137 states surveyed by the BTI are now ruled autocratically and are taking increasingly repressive action against the opposition, the media and civil society. Of these countries, 52 are hard-line autocracies in which fundamental rights are completely disregarded – more than at any time since the survey began in 2006. But autocratic tendencies are also gaining ground in numerous democracies. “Many elected governments have undermined core democratic institutions in order to stay in power, and this paves the way for autocracy,” says democracy expert Sabine Donner.

In 54 percent of the countries, elections no longer meet minimum standards. In some countries, such as Gabon or Niger, they were suspended after military coups, while in Belarus, Russia and Rwanda they are strictly controlled legitimizating rituals. However, numerous free and fair elections also led to peaceful changes of government. In Madagascar, Tanzania and Venezuela, mass protests following rigged elections were violently suppressed, but strengthened political mobilization beyond the election date.

Examples such as El Salvador, Serbia and Turkey show that the repeatedly touted promise of authoritarian efficiency is rarely fulfilled. Corruption is insufficiently combated in more than 100 countries, two thirds of which are autocracies. “In autocracies, loyalty must be rewarded and positions secured,” says BTI expert Hauke Hartmann. “The supposed efficiency of authoritarian regimes is a myth.”

However, persistent grievances continue to ensure that protests by dissatisfied citizens show no sign of abating. In Bangladesh, Nepal and Sri Lanka, protests forced a democratic opening, while a democratic turnaround was achieved in Brazil and Poland. “The BTI shows how much pressure democratic institutions are coming under – at the same time, we are seeing remarkably lively resistance to their erosion in many places,” says Daniela Schwarzer, Member of the Executive Board, Bertelsmann Stiftung. “This ability to mobilize, which comes above all from an active civil society, is a key potential for democratic renewal.”

www.bti-project.org

Additional information:
 Since 2006, the Bertelsmann Stiftung’s Transformation Index has analyzed the quality of democracy, market economy and governance in 137 countries every two years. Currently, 23 OECD countries, such as Germany and the USA, are not part of the study. The study was carried out between February 1, 2023 and January 31, 2025.

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/bertelsmann-stiftung-bti-survey-2026-more-autocracies-worldwide-but-democratic-resistance-is-growing/

Posted on

2026 Ningbo Image Overseas Exhibition Concludes Successfully in Hong Kong, China

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – On the afternoon of 21 March, the 2026 Ningbo Image Overseas Exhibition took place at the Hong Kong CineArt MegaBox. Using visual media as a connecting thread, the event built a bridge for cultural exchange between Ningbo and Hong Kong, allowing Hong Kong audiences to experience the charm of Ningbo up close.

The event comprised three components: a Ningbo-themed film screening, a creative salon, and the ‘Experience Ningbo’ city exhibition, attracting enthusiastic participation from staff and students of Hong Kong Baptist University, as well as local cultural figures.

The Ningbo-themed film screening presented three films from Ningbo and five short films from the 30°Ningbo Short Film Festival, showcasing Ningbo’s cultural heritage and natural scenery through the lens.

The creative salon invited three guests—director Jiang Xiaoxuan, Hong Kong Baptist University lecturer Lai Kin-fung, and Southern Film Company Limited‌ Manager Lin Yunhua—to explore new avenues for the visual dissemination of local culture from the perspectives of film and television production and the cultural fusion between the two regions.

The “Experience Ningbo” exhibition, through the promotion of local cuisine and scenic beauty alongside displays of urban cultural and creative products, allowed audiences to experience Ningbo through both sight and taste. Many visitors expressed their desire to visit Ningbo in person.

This event created a “visible, tangible and portable” record of the city’s culture, further deepening cultural exchanges between Ningbo and Hong Kong. Moving forward, the film exhibition will tour more overseas cities, using the medium of film to promote Ningbo to the world.

Hashtag: #2026NingboImageOverseasExhibition

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/2026-ningbo-image-overseas-exhibition-concludes-successfully-in-hong-kong-china/

Posted on

Boao: Where the World Meets | Qionghai: Where Free Trade Thrives

Source: Media Outreach

QIONGHAI, CHINA – Media OutReach Newswire – 26 March 2026 – From March 24-27, the ” Boao: Where the World Meets, Qionghai: Where Free Trade Thrives” City Exhibition was held at Boao’s Dongyu Island Cultural Park. This marks the first major city showcase since the launch of Hainan Free Trade Port’s island-wide special customs operations—providing a panoramic window into Qionghai’s role as a core functional zone of the free trade port. Woven with the theme of global connection and open development, the exhibition turns policies and culture into immersive, sensory experiences through innovative technology and design.

The opening hall’s “Digital Twin Experience Pod” offers a glimpse into daily life in tomorrow’s Qionghai—all through the use of an identity card. The interactive “Cycle Through Qionghai” installation takes guests on a dynamic ride along the Wanquan River, through historic Nanyang hometowns—settlements built by overseas Chinese returning from Southeast Asia, and into Qionghai’s stunning coastal and mountain scenery.

A key highlight is the frontier technology from the Boao Lecheng International Medical Tourism Pilot Zone. Breakthrough innovations—including the world’s first automatic exophthalmometer, a non-invasive glucose monitor, a facial recognition system for genetic screening, and the Ruiwatch wearable—made their collective public debut, showcasing how “global medical innovations meet their first patients in China.”

As China’s only Medical Tourism Special Zone, Qionghai is not just a hub of medical “tech marvels”—it is a natural wellness destination. It brings together world-class medical devices, privileged treatment policies, and international health management systems, making “access to global cutting-edge healthcare” an everyday reality. From Lecheng’s precision medicine to seaside healing, from Traditional Chinese Medicine wellness to sports recovery, Qionghai is building an integrated ecosystem of medical care, wellness, tourism, and living.

With the Free Trade Port now in full operation, this coastal city invites health seekers worldwide to begin a journey of total renewal—where advanced medicine meets natural vitality, right here in Qionghai.

Hashtag: #CultureandTourismofGuizhouProvince #Qionghai

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/boao-where-the-world-meets-qionghai-where-free-trade-thrives/

Posted on

Wellcome and COFCO Hong Kong Announce Strategic Partnership Target First-Year Sales to Exceed HK$100 Million

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Wellcome and COFCO Corporation Limited (“COFCO”) held a strategic cooperation agreement signing ceremony, announcing the establishment of a long-term partnership. The collaboration will strengthen cooperation across the supply of quality food products, brand and marketing initiatives, supply chain operations and elevating the overall customer consumption experience.

Curtis Liu, Chief Executive Officer, Food at DFI Retail Group (back row, fifth from left) and Mr. Lijun Qing, Vice President at COFCO Corporation Limited (back row, third from right) attended the signing ceremony with their teams to announce the strategic partnership

COFCO is an international agribusiness with a fully integrated food supply chain, underpinned by strong upstream sourcing capabilities and extensive supply chain management expertise. Wellcome is Hong Kong’s leading supermarket chain with the city’s largest store network. By leveraging their complementary strengths, the partnership aims to further enhance the supply of quality food products and offer customers a wider selection of fresh, great‑value choices.

Looking ahead, the two parties will focus on collaboration across four key areas:

  • First, strengthening the direct supply of quality products, with a diverse range of premium food products under COFCO prioritised for listing across Wellcome’s sales channels. This will expand offerings in key categories such as rice, flour, edible oils, dairy products, meat, alcoholic beverages, tea and beverages.
  • Second, enhancing supply chain efficiency by leveraging Wellcome’s local delivery and store network to accelerate the flow of fresh and fast‑moving consumer goods.
  • Third, driving joint brand and marketing initiatives, including new product launches, festive promotions and campaigns promoting healthy eating.
  • Fourth, strengthening food quality and safety management by strictly adhering to food safety standards and enhancing product traceability mechanisms, jointly safeguarding customers’ food safety.

At present, the key areas of cooperation include Mengniu dairy products, Fortune edible oil, Meilin canned food, and Joycome meat. In 2026, sales of COFCO’s products at Wellcome are expected to exceed HK$100 million. COFCO will prioritise supplying Wellcome with a broader range of quality products, while Wellcome will leverage its extensive local retail network to support COFCO with a stable and scalable sales channel in Hong Kong.

Through this partnership, both parties aim to provide customers with greater peace of mind and a wider range of quality food products, responding to Hong Kong families’ growing demand for better living. The first phase of the partnership’s promotional rollout features Joycome chilled pork, delivered fresh daily and offered at a long‑term promotional price of HK$28. Available from today at all Wellcome stores, the product is sourced directly from its origin, enabling Wellcome to offer customers produce of the highest quality.

Curtis Liu, Chief Executive Officer, Food, at DFI Retail Group, said: “This partnership between Wellcome and COFCO brings together the complementary strengths of both parties — COFCO’s robust food supply chain and Wellcome’s strong online and offline retail network. By combining these capabilities, we can further strengthen the stable supply of quality food products and offer customers a broader range of fresh products at great value.”

COFCO (Hong Kong) Limited’s spokesperson said: “The establishment of this long‑term strategic partnership with Wellcome fully leverages COFCO’s strengths in food supply chain capabilities and product resources, together with Wellcome’s territory‑wide retail network, enabling a wider range of quality food products to be supplied to the Hong Kong market more efficiently. COFCO will continue to provide Wellcome with a diverse and high‑quality product offering, working together to meet local households’ needs for food quality and supply stability.”

http://www.wellcome.com.hk
https://www.linkedin.com/company/wellcome-hong-kong/
https://www.facebook.com/wellcome.supermarket
https://www.instagram.com/hkwellcome/

Hashtag: #WellcomeHK #COFCO

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/wellcome-and-cofco-hong-kong-announce-strategic-partnership-target-first-year-sales-to-exceed-hk100-million/

Posted on

InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

Source: Media Outreach

BEIJING, CHINA – EQS Newswire – 26 March 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.

2025 marked InnoCare’s 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application (NDA) approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous “China First” achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth.

Financial Highlights

  • Revenue grew 135.3% year-on-year to RMB 2,375 million[1] in 2025, mainly driven by robust commercial growth and two strategic business development (BD) deals.
  • Profit reached RMB 644 million, achieving profitability for the first time, mainly due to significant commercialization growth and global out-licensing deals.
  • Gross Profit Margin increased by 5.7 percentage points to 92%.
  • Research and Development Investment increased by 16.9% to RMB 952 million in 2025, reflecting advancements of multiple Phase III registrational trials, as well as increased investments in new technology platforms such as ADCs and molecular glue.
  • Cash and Related Accounts Balance[2] stood at approximately RMB 7.8 billion as of December 31, 2025 and achieved positive operating cash flow for the first time. This strong cash position provides InnoCare with the flexibility to expedite global clinical development of key assets and invest in new technology platforms.

Accelerating Globalization with Transformative Deals

In 2025, InnoCare accelerated the implementation of its globalization strategy, unlocking global value of its core pipeline with two out-licensing deals, further enhancing the Company’s global influence and financial performance, and marking a significant step forward in its global expansion.

On Oct. 8, InnoCare entered into a transformative licensing agreement with Zenas for its autoimmune disease pipeline, including orelabrutinib. The agreement includes up to US$100 million in upfront and near-term milestone payments, and up to 7,000,000 shares of Zenas common stock, with a total deal value exceeding US$ 2 billion, setting a new record for small molecule autoimmune out-licensing in China.

This strategic collaboration marks a significant milestone in InnoCare’s globalization journey and will leverage shared focus to accelerate the global Phase III clinical development of orelabrutinib for the treatment of primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS), maximizing its clinical and commercial value worldwide, and advance a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor into clinical trials.

In addition, InnoCare entered into a licensing agreement with Prolium to further its global presence in 2025. In March 2026, Prolium announced first dosing of healthy volunteers in an ongoing single ascending dose study of ICP-B02 (PRO-203) and expects to initiate a multinational Phase I/II study of ICP-B02 in systemic sclerosis (SSc) in the second quarter of 2026, with additional studies in B-cell-driven autoimmune disease expected to follow.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “Building on an inspiring decade of solid growth, we have continuously enhanced our fully integrated platform ranging from original innovation, clinical development, commercialization, manufacturing, to business development, achieving our strategic goal of break-even ahead of schedule, marking a significant milestone in our development history. As we enter our 2.0 phase of rapid development, we are focused on key strategic priorities, including securing approvals for five to six innovative drugs, advancing three to four products globally, and progressing five to ten differentiated molecules into clinical trials. We will further accelerate globalization, significantly increase revenue, and deliver more high-quality innovative therapies to benefit patients worldwide. “

Building A Leading Franchise in Hemato-Oncology

In 2025, InnoCare made significant progress toward building a leading hemato-oncology franchise, driven by advances in commercial execution, late-stage clinical development, and global expansion.

InnoCare continued to strengthen its commercial portfolio with orelabrutinib approved for first line chronic lymphocytic leukemia/small lymphocytic lymphoma (1L CLL/SLL) and successfully included in the updated National Reimbursement Drug List (NRDL), while tafasitamab became the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in China. As a result, drug sales increased by 43.4% to RMB 1,442 million in 2025.

Mesutoclax (ICP-248), the first BCL2 inhibitor granted Breakthrough Therapy Designation in China, continues to advance across multiple indications, including CLL/SLL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), with clinical trials ongoing in China and globally. Together, these three assets form the core of InnoCare’s hemato-oncology strategy, supporting near-term revenue growth with a pipeline of differentiated, late-stage therapies.

Orelabrutinib

Orelabrutinib serves as a backbone therapy in InnoCare’s extensive hemato-oncology pipeline. Its newly approved 1L CLL/SLL indication has been included in the NRDL and is recommended as a Class I treatment in the Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma. With all four approved indications now covered under the NRDL, orelabrutinib offers stable annual treatment costs, benefiting more lymphoma patients.

The commercial team further strengthened execution capabilities and sharpened strategic focus, delivering strong sales performance throughout 2025. Improved market penetration and operational discipline laid a solid foundation for sustained revenue growth and long-term commercial success.

Internationally, orelabrutinib continued to expand its regulatory footprint, with approval granted for relapsed or refractory marginal zone lymphoma (R/R MZL) in Singapore and NDA submission for R/R MCL successfully completed in Australia.

Tafasitamab

In May 2025, the tafasitamab regimen received NDA approval for adult patients with R/R DLBCL, representing the first CD19 antibody therapy approved in China for this indication and a key addition to InnoCare’s commercial portfolio.

Building on the initial commercial launch in September 2025, 2026 will mark the first full year of tafasitamab sales in China. Moreover, tafasitamab has been included as a Class II recommendation in the CSCO Guidelines, which will help address unmet clinical needs in this patient population and provide meaningful benefits.

Mesutoclax (ICP-248)

As the first BCL2 inhibitor granted BTD in China, mesutoclax has rapidly advanced across multiple registrational studies. The Phase III combination regimen with orelabrutinib for 1L CLL/SLL completed patient enrollment within 10 months, demonstrating strong clinical execution. This fixed-duration combination regimen has the potential to deliver deeper remissions, bringing hope for clinical cure and representing a promising treatment option.

A registrational trial in BTK inhibitor-treated MCL is progressing rapidly, and a Phase III randomized, double-blind, multicenter study of mesutoclax in combination with orelabrutinib versus pirtobrutinib (a reversible BTK inhibitor) in r/r MCL is expected to commence in 2026.

Global development of mesutoclax in AML and MDS is progressing across China, U.S., and Australia. The global AML and MDS markets are projected to reach US$8 billion[3] and US$11 billion[4] by 2034 respectively.

Mesutoclax, as a monotherapy or in combination with orelabrutinib, demonstrated a favorable safety profile for CLL/SLL across all dose levels tested. In the CLL/SLL patients receiving mesutoclax in combination with orelabrutinib, the overall response rate (ORR) was 100%, the complete response rate (CRR) was 57.1%, and the peripheral blood uMRD rate at 36-week was 65%. The clinical data from mesutoclax monotherapy demonstrated potential best in class efficacy in MCL patients, particularly in heavily treated patients with BTK inhibitor refractory. Among MCL patients who were BTK inhibitor-refractory, the ORR was 84.0% and the CRR was 36.0%. Mesutoclax in combination with orelabrutinib demonstrated a consistently favorable safety profile across B-cell malignancies (MCL, MZL, CLL/SLL). This oral, chemo-free regimen has the potential to establish a novel therapeutic option for B-NHLs. Updated data will be presented at 2026 American Society of Clinical Oncology (ASCO) annual meeting.

The combination of mesutoclax and azacitidine demonstrated a favorable safety profile and encouraging anti-tumor activity not only in AML but also in MDS patients. Among 35 evaluable treatment-naive AML patients, the regimen achieved an 85.7% composite CR rate and an 86.7% uMRD rate, with no mortality observed with 90 days. Preliminary data among MDS patients is also promising. There were no dose-limiting toxicities (DLT) or tumor lysis syndrome (TLS) events. Detailed data to be presented at 2026 ASCO annual meeting.

Developing B-cell and T-cell Pathways in Autoimmune Diseases

Autoimmune diseases can affect almost every organ in the body and may arise at any stage of life. The global market for autoimmune disease therapeutics is anticipated to reach $185 billion by 2029[5]. The Company has fortified its powerful discovery engine on cutting-edge global targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with the aim of delivering first-in-class and/or best-in-class treatments to address the massive unmet clinical needs and strong market potential in China and globally.

Orelabrutinib

Immune Thrombocytopenia (ITP): With over 200,000 new cases globally each year, including 60,000 in China, ITP represents a significant unmet medical need. The pivotal Phase III study has been completed, and the Company expects to submit the NDA application in the first half of 2026. ITP represents an important expansion of orelabrutinib from hematologic malignancies into autoimmune hematologic diseases, unlocking its enormous commercial potential. By leveraging the BTK inhibitor’s advantage in ITP, such as decreased macrophage-mediate platelet destruction and reduced production of pathogenic autoantibodies, orelabrutinib is well positioned to become a preferred BTK inhibitor in the field of ITP.

Systemic lupus erythematosus (SLE): There are about 8 million SLE patients worldwide. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase II clinical trial for SLE. The Phase IIb study met its primary endpoint, and a Phase III registrational study was initiated in the first quarter of 2026. Under stringent steroid-tapering requirements, orelabrutinib 75 mg once daily (QD) achieved a statistically significant improvement in SLE Response Index-4 (SRI-4) rate compared with placebo at Week 48 (57.1% vs. 34.4%, p

Multiple Sclerosis (MS): The US SPMS and PPMS market exceeds US$12 billion[6], representing a significant commercial opportunity. Based on the deal, InnoCare has been cooperating with Zenas to accelerate two global Phase III clinical trials of orelabrutinib for the treatment of PPMS and SPMS, further unleashing its global value in autoimmune diseases.

  • Initiated Orelabrutinib PriMroSe PPMS trial, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with PPMS in the third quarter of 2025. More information on the Phase III PriMroSe trial (NCT07067463) is available at clinicaltrials.gov.
  • Orelabrutinib Monarch trial for non-active SPMS (naSPMS) is planned, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with naSPMS is expected to initiate in the first quarter of 2026. More information on the Phase III Monarch trial (NCT07299019) is available at clinicaltrials.gov.

Two TYK2 Inhibitors

The global dermatology drug market has enormous potential, with over 500 million patients suffering from dermatological diseases worldwide. By 2035, the global dermatology market size is projected to reach nearly US$100 billion. InnoCare is well positioned to capture this opportunity with two TYK2 inhibitors targeting multiple high-value indications, including atopic dermatitis (AD), psoriasis, vitiligo, nodular prurigo (PN), urticaria (CSU), cutaneous lupus erythematosus (CLE), and other dermatological diseases. The global AD market is projected to reach $30 billion[7] by 2030, the vitiligo market $3 billion[8] by 2032, the CSU market $3 billion[9] by 2029, the psoriasis market $58 billion[10] by 2032, the PN market $3 billion[11] by 2034, and CLE market US$ 7.9 billion[12] by 2032.

Soficitinib (ICP-332)

The Phase III clinical study of soficitinib in patients with moderate to severe atopic dermatitis (AD) completed patient enrollment, with data readout expected in mid-2026. The Phase II clinical study of soficitinib in patients with vitiligo has also completed patient enrollment. Additional studies in prurigo nodular, urticaria, and psoriasis are progressing rapidly. As a result, soficitinib is expected to deliver a series of clinically meaningful data catalysts in 2026.

Data from the Phase II clinical trial of soficitinib in patients with moderate-to-severe AD were published in JAMA Dermatology in January 2026. The journal concluded that soficitinib demonstrated a favorable safety profile and encouraging efficacy in patients with AD.

Soficitinib achieved multiple efficacy endpoints in the study. The percentage improvement from baseline in EASI at Week 4 were 78.2% in the soficitinib 80 mg group, 72.5% in the soficitinib 120 mg group, and 16.7% for those receiving placebo. There was a statistically significant higher EASI-75 response rate with both soficitinib doses (64.0% for each; difference vs placebo, 56.0%) than with placebo and a greater percentage of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA) score of 0 or 1 and improvement of 2 or more points at Week 4 in the soficitinib 80 mg group vs placebo (36.0%; difference vs placebo, 32.0%, P=0.005). Meanwhile, soficitinib demonstrated rapid relief of pruritus and significant improvement in quality of life. Substantial reductions in Pruritus NRS severity and frequency scores were observed on Day 2 of treatment compared to placebo, with continued improvement over time, peaking at Week 4 for both severity and frequency (all P

ICP-488

The Phase III clinical study in psoriasis has completed patient enrollment, and the Phase II trial for CLE is progressing rapidly. The IND for Sjögren’s syndrome has been submitted, and additional indications and combination strategies are under evaluation.

Data on ICP-488 for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 AAD Annual Meeting as a late-breaking oral presentation. The study results demonstrated that ICP-488 is highly effective in treating psoriasis at both the 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.

At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%).

ICP-538

The first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of the VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Currently, there are no approved VAV1-targeted therapies globally.

ICP-054

The IND application of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor, was submitted. ICP-054 is a novel, oral, highly potent and selective IL-17AA/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases. ICP-054 can effectively block the signal transduction pathways of IL-17AA homodimer and IL-17AF heterodimer, thereby inhibiting the release of pro-inflammatory cytokines and chemokines, exerting an anti-inflammatory effect. Simultaneously, it reduces excessive proliferation of keratinocytes and inflammatory cell infiltration, improving skin lesions and thus suppressing the occurrence of autoimmune and inflammatory diseases.

Under the BD agreement, Zenas holds exclusive rights to develop, manufacture and commercialize the oral, IL-17AA/AF inhibitor in all territories outside Greater China and Southeast Asia.

Building Innovative Solid Tumor Assets

InnoCare has been building a robust and diversified portfolio to address significant unmet medical needs across multiple tumor types. The Company is committed to combining targeted small molecules with next-generation antibody-drug conjugates (ADCs) to maximize clinical benefit while minimizing systemic toxicity. The R&D team aims to focus on tumor types with high unmet needs, and to develop therapies that are differentiated in mechanism of action, potency, and safety profile. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like zurletrectinib, positions the Company to establish a strong presence in the field of solid tumor treatment.

Zurletrectinib (ICP-723)

Zurletrectinib, a next generation TRK inhibitor, represents InnoCare’s first approved therapy in solid tumors and its third innovative product approved for marketing. Zurletrectinib is indicated for adult and adolescent patients (12–18 years) with NTRK gene fusion-positive tumors.

In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an ORR of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively.

InnoCare expects to submit NDA for pediatric patients (2 years

In-House Developed Antibody-Drug Conjugate (ADC) Platform

The Company has developed a cutting-edge ADC platform with proprietary linker-payload (LP) technologies, aimed at the delivery of potent and targeted therapies for cancer treatment. This platform allows for the creation of highly differentiated ADCs with improved efficacy and safety profiles. Key features of the platform include:

  • Irreversible bioconjugation: ensuring stable antibody-linker bioconjugation for improved stability.
  • Hydrophilic linker: enhancing ADC stability and achieving a high drug-to-antibody ratio (DAR) of 8.
  • Novel payload: incorporating highly potent cytotoxic payloads with a strong bystander killing effect.

The platform is expected to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology.

ICP-B794: A Novel B7-H3 Targeted ADC for Solid Tumors

InnoCare is advancing the Phase I dose escalation trial of novel B7-H3 targeted ADC, ICP-B794. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to a potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others. ICP-B794 has demonstrated superior anti-tumor activity in animal models compared with other ADCs, and exhibited significant tumor-killing effects even in large tumors.

Early clinical observations indicate favorable pharmacokinetics and tolerability, with preliminary signs of antitumor activity, which validate the Company’s proprietary ADC platform for solid tumor development.

ICP-B208: A Novel CDH17 Targeted ADC for Solid Tumors

Building on the encouraging efficacy and safety of ICP-B794, the second ADC candidate, ICP-B208, is designed to target CDH17, a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, enabling the delivery of potent cytotoxic payloads specifically to tumor cells while minimizing systemic toxicity, which can be developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. Preclinical studies show that ICP-B208 demonstrates good anti-tumor activity even in CDH17-low tumors. The IND application has been submitted in March 2026.

InnoCare plans to submit at least two more ADC INDs within 2026, further expanding its differentiated solid tumor pipeline.

To know more about the detailed financial data and business updates of InnoCare 2025 annual results, please log in to https://www.innocarepharma.com/en/investor/home .

Conference Call Information

InnoCare will host a conference call at 8:30 p.m. Beijing time on March 25 in English and at 9:00 a.m. Beijing time in Chinese on March 26, 2025. Participants must register in advance of the conference call. Details are as follows:

For English conference call, please register through the below link:
https://goldmansachs.zoom.us/webinar/register/WN_rVCbaOqMSM-QJQlfzlTEvw

For Chinese conference call, please register through the below link:
https://s.comein.cn/qz7duugd

Forward-looking Statement

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

[1] The financial figures in this article are based on Hong Kong Financial Reporting Standards

[2] Include cash and bank balances, other current assets, financial assets among other non-current assets, and interest receivable

[3] Global Growth Insights

[4] Nova One Advisor, Insight Code: 8817

[5] iHealthcareAnalyst, Inc., Oct. 3, 2023

[6] Zenas estimate based on reported prevalence and current pricing of B cell therapies approved for MS

[7] Grand View Research

[8] Data Bridge Market Research

[9] The Business Research Company

[10] Fortune Business Insights

[11] Global Market Insights

[12] Data Bridge Market Research

Hashtag: #InnoCare

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/innocare-releases-2025-results-and-business-highlights-achieving-first-annual-profit/

Posted on

Zuellig Pharma Reinforces Commitment to Japan through Its New Misato Depot, Advancing Clinical Logistics and Sourcing Excellence

Source: Media Outreach

MISATO, JAPAN – Media OutReach Newswire – 26 March 2026 – Zuellig Pharma today announced the successful relocation of its new clinical depot to Misato, strengthening its ability to deliver global quality standards with local operational agility and further strengthening its clinical supply capability across Asia Pacific. Japan remains one of the region’s preferred locations for clinical research, underpinned by its strong focus on medical advancement, rigorous ethical standards and commitment to healthcare.

Medical innovation across the region continues to accelerate, with China, India, Australia, Japan, South Korea, Taiwan and Singapore emerging as key pillars of Asia Pacific’s clinical trial ecosystem over the past five years[1]. Against this backdrop, the move in Japan reinforces Zuellig Pharma’s commitment to supporting sponsors and clients with reliable, compliant and seamless access to Japan – advancing its broader mission to make healthcare more accessible.

The new depot will bring together Zuellig Pharma’s established knowledge assets, operational excellence, and clinical logistics and sourcing expertise. Backed by a highly experienced and expert-led local team, the depot delivers precision project management tailored to Japan’s intricate regulatory and logistical requirements, while enabling smoother coordination for multi-market studies as the clinical landscape continues to evolve.

“As sponsors and clients increasingly run multi-market studies, they need clinical supply partners that can deliver consistency across borders while navigating local complexity,” said John Graham, Chief Executive Officer, Zuellig Pharma. “This relocated depot will strengthen access to Japan within our regional network, helping us execute with greater reliability, compliance, and speed across the region.”

The Misato clinical depot will also provide a streamlined, turnkey solution for global sponsors seeking rapid and compliant market entry into Japan. Sponsors will benefit from the same rigorous operational excellence, regulatory adherence, and service consistency delivered by Zuellig Pharma’s strategic network of clinical depots, without the overhead of building or managing costly standalone facilities. This milestone supports Zuellig Pharma’s ongoing efforts to accelerate clinical development and improve patient access to innovative therapies across Asia Pacific.

With this strategic move, Zuellig Pharma further strengthens its position as a trusted partner for global clinical development, combining scale, expertise, and agility whilst delivering high-quality, compliant clinical logistics and sourcing solutions across Asia Pacific.

[1] https://www.clinicaltrialsarena.com/features/apac-clinical-trials-beyond-china

https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma

Hashtag: #ZuelligPharma #ClinicalTrials #ClinicalResearch #Healthcare #Pharmaceuticals #ColdChain #Logistics

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/zuellig-pharma-reinforces-commitment-to-japan-through-its-new-misato-depot-advancing-clinical-logistics-and-sourcing-excellence/

Posted on

Contractor Confidence Rises Amid Strengthening Office Demand Across Asia Pacific

Source: Media Outreach

  • Contractor Sentiment Survey shows 70% of respondents expect improved market conditions in 2026
  • Office fit out costs diverge across the region with Japan and Taipei posting largest year-on-year increases while costs in Hong Kong held steady

HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Cushman & Wakefield’s Asia Pacific Office Fit Out Cost Guide 2026 highlights a clear shift in regional market dynamics, with sentiment strengthening and activity levels improving across several key markets. Contractor confidence has risen year-on-year, with 70% of the respondents to the firm’s annual Contractor Sentiment Survey anticipating improved conditions in 2026. This positive sentiment is further supported by the stronger‑than‑expected 92 million square feet of office absorption in 2025 and a tightening construction pipeline outside India.

Of the 180 survey respondents, nearly two thirds reported project backlogs of around six months, reflecting improving project delivery conditions across the region. While Japan and Indonesia remain outliers with longer backlogs, most markets expect stabilisation or slight improvement in delivery timelines in 2026. This alignment between contractor sentiment and strengthening occupier demand points to a more balanced and active project environment emerging across Asia Pacific.

Ranee Ng, Executive Director, Head of Project & Development Services, Hong Kong said: “As Hong Kong’s property market evolves, occupiers are seeking practical, scalable fit out strategies that deliver efficiency in high density environments. There is a clear shift toward flexible designs that can rapidly adapt to changing workforce behaviours and policy updates, while demand for sustainable materials, energy efficient construction and smart building technologies is accelerating innovation. These trends are creating a more resilient fit out ecosystem where disciplined cost management and value driven delivery allow clients to achieve compelling performance outcomes without sacrificing quality.”

Fit Out Cost Movements (YoY, 2025 → 2026)

The 2026 Guide reported a divergence in city level fit out costs (measured in USD per sq ft) across the region:

  • Costs rising: Japan and Taipei posted the largest year-on-year increases
    (Tokyo: USD 215 vs USD 195; Taipei: USD 145 vs USD 110)
  • Costs easing: Mainland China and South Korea saw declines
    (Shenzhen: USD 87 vs USD 94; Seoul: USD 130 vs USD 156)
  • Costs steady: Singapore (USD 140) and Hong Kong (USD 160) remained largely unchanged
  • Best value: India remains the region’s most cost competitive market, with most major cities ranging USD 65–73 per sq ft

These cost movements reflect evolving local construction dynamics and broader economic adjustments influencing material, labour and delivery markets across Asia Pacific.

APAC Office Market Dynamics

Even as office demand across APAC surged in 2025, Cushman & Wakefield also noted a substantial contraction in new office supply outside India. Development pipelines have moderated sharply due to rising construction costs and reduced project feasibility, intensifying competition for prime space. As supply tightens, vacancy rates in high quality buildings – particularly in core CBD locations – are expected to trend lower, reinforcing the ongoing flight to quality amongst occupiers.

Report author and Head of International Research, APAC & EMEA, Dr. Dominic Brown said: “After a resilient 2025, the Asia Pacific office market is now transitioning into a more stable phase, supported by a gradual return of business confidence. Coupled with the tightening supply pipeline outside India, which is reshaping the competitive landscape for high quality space, these collective shifts indicate a meaningful turning point for the region in 2026, with both occupiers and investors positioned for renewed momentum.”

Notes:

  1. Data and pricing benchmarks in the guide reflect market conditions as of December 2025. For insights on the Middle East conflict, please refer to Cushman & Wakefield’s Middle East Conflict: Implications for Energy, Inflation, and CRE.
  2. Cushman & Wakefield publishes Office Fit Out Cost Guides for APAC, EMEA and the Americas, which are all available [here].

Hashtag: #CushmanWakefield

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/contractor-confidence-rises-amid-strengthening-office-demand-across-asia-pacific/

Posted on

Felix Y. Manalo Foundation: How Education-Focused Humanitarian Programs Break Cycles Of Poverty

Source: Media Outreach

MANILA, PHILIPPINES – ACCESS Newswire – 25 March 2026 – Poverty is possibly the most significant limiting factor in terms of access to learning, healthcare, and economic mobility. In less-advantaged communities, education-centered humanitarian programs are necessary to address these constraints.

The Felix Y. Manalo Foundation operates at the forefront of these initiatives by building practical skills, supporting youth development, and strengthening community capacity. In its role as a catalyst for long range social progress, it incorporates academic support, volunteer service, and community outreach within its broader humanitarian mission.

Expanding Access to Learning Resources

For many low-income households, limited access to books, digital tools, and structured learning environments remains a major hindrance to growth and development. Through its educational outreach programs, organizations such as the Felix Y. Manalo Foundation provide learning materials, organize community-based activities, and support youth engagement initiatives that reinforce academic participation.

These efforts can greatly reduce disparities that commonly exist between urban and underserved communities. By providing students with consistent access to educational resources, the foundation helps improve attendance, increase confidence, and pave the way for long-term career paths.

Integrating Skills Development With Community Service

The Felix Y. Manalo Foundation’s approach to education extends beyond classroom instruction, delving into practical experience that encourages problem-solving and teamwork. Program participants have the opportunity to join service projects that introduce responsibility, planning, and communication.

The foundation also implements environmental programs, food distribution activities, and local outreach events, all of which provide structured opportunities for applied learning. By integrating mentorship with volunteer guidance, the organization teaches participants valuable, transferable skills. Consequently, the programs foster workforce readiness while strengthening civic awareness and social responsibility.

Stabilizing Families Through Supportive Outreach

Organizations such as the NIH attest to the beneficial impact of household stability on student performance and long-term educational attainment. Food assistance initiatives, health awareness programs, and community support events can all reduce financial strain and promote well-being among disadvantaged families.

The Felix Y. Manalo Foundation’s coordinated food donation programs and volunteer engagement activities in Canada demonstrate how relief efforts enhance household resilience. By addressing basic needs alongside educational outreach, the organization helps develop environments where children can focus on learning rather than worry about their immediate survival.

Operational Discipline and Program Sustainability

The Felix Y. Manalo Foundation’s community service amply demonstrates the value of structured planning, transparent governance, and reliable volunteer coordination. To ensure sustainable impact, accountability has always been core to the organization’s project management, financial stewardship, and compliance practices.

The foundation’s training frameworks are designed to ensure consistent service quality and reinforce ethical standards. Through its organizational oversight, the organization fosters donor confidence and maintains continuous improvement in its education-focused programs.

Through its various education-centred humanitarian programs, the Felix Y. Manalo Foundation directly contributes to economic mobility by improving home stability, increasing community participation, and strengthening individual capability. By integrating learning access with service engagement and operational accountability, the organization ensures the community’s long-term development is measurable and scalable.

Structured educational outreach, volunteer leadership development, and responsible governance are among the practical measures implemented by the Felix Y. Manalo Foundation. Each is one of many ways the organization aims to break cycles of intergenerational poverty while supporting inclusive community growth.

Hashtag: #FelixY.ManaloFoundation

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/felix-y-manalo-foundation-how-education-focused-humanitarian-programs-break-cycles-of-poverty/

Posted on

ASMALLWORLD Introduces New Marriott Bonvoy® Benefit for Members

Source: Media Outreach

ZURICH, SWITZERLAND – EQS Newswire – 25 March 2026 – ASMALLWORLD expands its offering with a new Marriott Bonvoy reward expanding its curated portfolio of premium travel benefits and loyalty rewards available across the ASMALLWORLD travel ecosystem.

ASMALLWORLD members can now enjoy access to Marriott Bonvoy points as part of their membership benefits — 35,000 points (Advantage), 250,000 points (Prestige) and 500,000 points (Signature) — bringing added flexibility and value for members who want to elevate their hotel stays worldwide.

“This new benefit marks another important step in strengthening our global travel benefits portfolio and giving members more meaningful ways to unlock exceptional experiences,” said Zain Richardson, CEO of ASMALLWORLD. “By integrating Marriott Bonvoy points into our product offering, we are increasing choice and helping our members turn travel inspiration into memorable stays — whether for a long weekend or a once-in-a-lifetime journey.”

NEW MARRIOTT BONVOY BENEFIT FOR ASMALLWORLD MEMBERS

Marriott Bonvoy is Marriott International’s award-winning travel programme, spanning a global collection of hotel brands and destinations.

Through this partnership, ASMALLWORLD members can include Marriott Bonvoy points as part of their membership benefits, enabling them to use points toward stays that include the largest collection of luxury offerings, distinctive boutique properties, premium home rentals, and more. Members can also unlock once‑in‑a‑lifetime experiences through Marriott Bonvoy Moments , from exclusive Michelin‑starred culinary journeys to groundbreaking musical world tours. Expanded ways to redeem points range from Shop with Points to curated Tours & Activities, adding another layer of memorable experiences to the ASMALLWORLD membership proposition.

MARRIOTT BONVOY POINTS PACKAGES AVAILABLE TO MEMBERS

ASMALLWORLD members can access the following Marriott Bonvoy points packages as part of their membership selection:

To celebrate the launch of this new benefit, ASMALLWORLD members purchasing Advantage or Prestige memberships will receive a limited time award of 30% bonus points.

EXPANDING PREMIUM TRAVEL BENEFITS

This new benefit reinforces ASMALLWORLD’s commitment to offering members a curated suite of travel privileges across flights, hotels, experiences and lifestyle.

In addition to loyalty rewards, ASMALLWORLD members enjoy a range of premium benefits across the ASMALLWORLD ecosystem, including VIP hotel benefits, elite statuses, airport lounge access options and invitations to exclusive global events.

THE ASMALLWORLD GROUP

Centred around the ASMALLWORLD social network, the company operates a luxury travel ecosystem that serves discerning travellers and industry partners.

At its core, the ASMALLWORLD social network is the trusted community for modern luxury travellers, offering a platform to connect, share experiences and enjoy a wealth of travel privileges.

ASMALLWORLD members can engage through its app and website, receive travel inspiration, and meet in person at over 950 global ASMALLWORLD events every year, ranging from casual get-togethers, access to exclusive launches, galas, major global sporting events, and larger flagship weekend experiences hosted in iconic destinations such as Saint-Tropez and St. Moritz.

Beyond the social network, the ASMALLWORLD Group extends into bespoke travel planning, luxury hospitality, and strategic B2B collaborations. Through its diverse portfolio, the Group fosters a like-minded global community, curated opportunities, and tailored solutions, shaping the evolution of luxury travel.

Other businesses in the ASMALLWORLD travel ecosystem include:
ASMALLWORLD Collection, a high-end online hotel booking engine focused on the world’s most admired hotels, offering the unique “ASMALLWORLD VIP Rate,” which combines preferred rates with exclusive travel benefits and privileges.

ASMALLWORLD Bespoke Travel, a high-end travel agency offering personalised travel curation services.

ASMALLWORLD DISCOVERY, part of Global Hotel Alliance alongside 50 leading hotel brands, services independent hotels in providing access to the GHA DISCOVERY loyalty network

ASMALLWORLD Hospitality, a hospitality and management consultancy that supports owners and developers of hospitality assets throughout the different lifecycle stages of their assets, including acquisition, development, operations and exit.

First Class & More, a subscription-based smart luxury travel service that allows members to enjoy luxury travel at insider prices.

The World’s Finest Clubs, the world’s leading nightlife concierge offers its members VIP access to the most exclusive nightlife venues around the world.

Jetbeds, a premier booking platform specialising in affordable Business and First-Class flights, offering exclusive deals, expert advice and personalised service.

For more information, please visit:www.asmallworldag.com / www.asmallworld.com

CONTACTS
ASMALLWORLD AG
Seidengasse 20
8001 Zurich
Switzerland
info@asmallworldag.com

Pippa O’Keefe
Head of PR
+44 7990 824 249
pippa@asw.com

DISCLAIMER
The statements contained in this press release may constitute “forward-looking statements”. Such can be identified, for example, by the use of the words “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “target,” “seek,” or “aim,” or the negative of these words or comparable expressions.

Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Issuer or its industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by such forward-looking statements.

The issuer undertakes no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/asmallworld-introduces-new-marriott-bonvoy-benefit-for-members/

Posted on

Tintri and Integration Plumbers Announce Groundbreaking Open-Source Integration to Unify Storage and IT Observability

Source: Media Outreach

Delivering unprecedented full-stack visibility, the new OpenTelemetry-based solution eliminates storage silos, accelerates troubleshooting, and empowers IT teams with a seamless, vendor-agnostic monitoring pipeline.

AMSTERDAM, NETHERLANDS – Media OutReach Newswire – 25 March 2026 – Tintri, innovator of the industry’s only workload-aware, AI-powered data management platform for virtualized and containerized workloads, today announced a strategic partnership with Integration Plumbers, observability integration specialists. Together, the companies have launched a highly anticipated, no-cost, and open-source integration designed to seamlessly connect Tintri’s intelligent VMstore platform to the modern monitoring ecosystems that enterprise IT teams rely on daily.

This collaboration marks a significant milestone in enterprise infrastructure management, bridging the historical gap between storage arrays and application-level observability. By leveraging open standards, Tintri and Integration Plumbers are delivering maximum visibility without the burden of proprietary dependencies.

The Problem: Too Many Dashboards, Not Enough Answers

In today’s hyper-complex, cloud-native IT environments, every minute of downtime or performance degradation translates directly to lost revenue and diminished user experience. When an incident occurs, rapid root-cause analysis is critical. However, for many organizations, determining whether a performance bottleneck originates in the application code, the network layer, or the underlying storage system is a convoluted, manual process.

Historically, storage monitoring has existed in a vacuum. Storage administrators utilize specialized, vendor-specific dashboards, while DevOps and Site Reliability Engineering (SRE) teams rely on entirely different platforms for application and infrastructure monitoring. This fragmentation forces teams to log into multiple disconnected tools, manually correlate timestamps, and engage in time-consuming cross-departmental coordination. The result is a bloated Mean Time To Resolution (MTTR), increased operational costs, and unnecessary architectural complexity. IT teams are burdened with managing disparate monitoring systems, redundant alerts, and separate credentials just to piece together a holistic view of their infrastructure.

The Solution: One Pipeline for Everything

The newly announced integration fundamentally transforms this paradigm by establishing a single, unified pipeline for all telemetry data. Built natively on OpenTelemetry, the rapidly adopted open industry standard for collecting, processing, and routing monitoring data; this solution ingests Tintri’s granular storage metrics directly into the existing observability pipelines that IT teams already use.

Rather than forcing engineers to consult a separate “storage only” application, this integration acts as a seamless data feed into a centralized command center. Tintri’s VMstore is architected to track performance at the level of individual virtual machines and containerized applications, eschewing the traditional, opaque LUN or volume-level metrics. The data it generates is uniquely detailed, context-rich, and immediately actionable.

This integration effortlessly surfaces VMstore’s rich telemetry in whatever monitoring platform an enterprise has already standardized on, such as Grafana, Datadog, Dynatrace, Prometheus, and any other OpenTelemetry-compatible tool.

Phil Trickovic, Senior Vice President, Tintri stated: “Storage telemetry has historically been stuck in vendor-specific silos. This integration changes that, giving platform and operations teams a unified view of their entire stack, including storage, without adding new tools or new contracts.”

What This Means in Practice: Tangible Business Value

The Tintri and Integration Plumbers partnership delivers immediate, measurable benefits to enterprise IT operations:

  • Faster Troubleshooting and Reduced MTTR: When an incident occurs, IT teams can now visualize storage performance data side-by-side with application and infrastructure telemetry in a single, unified dashboard. This contextualized view drastically cuts the time required to identify and remediate root causes.
  • Zero Additional Licensing Costs: The integration is designed to work flawlessly with the monitoring platforms customers already have deployed. No need to procure, deploy, or train staff on a separate, standalone storage monitoring product.
  • Total Freedom and Flexibility: Because the solution is built entirely on the OpenTelemetry open standard, customers are protected from vendor lock-in. Should an organization decide to migrate to a different monitoring vendor in the future, the transition requires only a simple configuration update, not a complete architectural overhaul.
  • Built to Last and Evolve: By contributing this integration directly to the open-source OpenTelemetry community, Tintri and Integration Plumbers foresee the tool continuously evolving alongside broader industry standards, rather than being constrained by a single vendor’s proprietary roadmap.

Under the Hood: Built on OpenTelemetry Standards

For platform engineers and technical architects, the integration is engineered as a standard OpenTelemetry Collector component. It intelligently harvests metrics from both physical VMstore appliances and the Tintri Global Center management platform via robust REST APIs.

Crucially, these metrics are meticulously mapped to OpenTelemetry semantic conventions. This standardization enables out-of-the-box correlation with Kubernetes environments and application-level telemetry. Standard Collector exporters facilitate the seamless routing of this data to any OTLP-compatible backend including Prometheus, ClickHouse, Datadog, and Dynatrace; requiring absolutely no modifications to the Tintri integration itself.

Demonstrating a profound commitment to the open-source ethos, the project will be officially contributed to the OpenTelemetry ecosystem. It is architected from the ground up for long-term community maintainability and strict compliance with OTEL project standards.

Trickovic elaborated “By combining Tintri’s workload-aware storage metrics with the OpenTelemetry ecosystem, we’re giving customers the unified observability they’ve been asking for – storage shouldn’t be the blind spot in your monitoring stack.”

Tintri and Integration Plumbers will be hosting a 60-minute deep dive into OpenTelemetry-native storage observability, including a live technical demo on April 15, 2026 at 10:00 AM PT / 1:00 PM ET. https://tintri.com/experience/tintri-integration-plumbers-4-15-26/

Hashtag: #Tintri #IntegrationPlumbers

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/tintri-and-integration-plumbers-announce-groundbreaking-open-source-integration-to-unify-storage-and-it-observability/

Posted on

Tintri and Platform9 Announce Joint Solution for containerized and hypervisor-based workloads.

Source: Media Outreach

New all-in-one platform to help businesses develop and deploy at scale with maximum ROI

CHATSWORTH, US – Media OutReach Newswire – 25 March 2026 – Tintri, the innovator in workload-aware, AI-powered data management, and Platform9, the leader in simplifying enterprise private clouds, today announced a strategic partnership to deliver a bundled AI-ready infrastructure solution that streamlines deployment and reduces operational costs. The out-of-the-box offering makes it simple for enterprises to stand up and scale modern AI systems without the complexity of traditional stacks.

The Problem: AI Is Getting Expensive

Running AI to process and analyze data in real time, requires moving enormous amounts of data at extremely high speeds. Existing infrastructure wasn’t built to manage the sheer volume and velocity of data required for on-demand inferencing and ongoing model training, ultimately causing slowdowns and driving up operational costs. Tintri and Platform9 directly addresses these critical bottlenecks in the by cutting the cost per AI transaction, as low as possible.

What’s in the New Platform

The new offering has two main parts:

1. A powerful data center component built on standard server hardware that can run multiple types of virtual machines and containerized applications side-by-side, without resource impacts. Tintri’s patented technology monitors each application individually, making sure the most critical ones always get the resources they need.

2. An edge AI component designed for capturing real-time data to continuously learn and update inference models.

A core component of the platform is Tintri VMstore, which uniquely runs multiple virtualization platforms and Kubernetes (the industry-standard system for managing containerized applications) all within the same platform. This is a significant differentiator: most competing solutions require separate infrastructure for each. Tintri’s patented technology observes each application individually and guarantees real-time resource delivery, even when the system is under heavy load. This eliminates the “noisy neighbor” problem, where resource-intensive applications steal resources and slow down everything else.

Why It Matters

Many companies today have AI running in multiple locations, either in a central data center, as well as out in the field on cameras, sensors, or other devices. Managing all of that separately is complex and expensive. This new platform unifies the entire setup under one management system (provided by Platform9), so IT teams spend less time juggling tools and more time moving their business forward.

Available now through Tintri’s global network of authorized partners, Phil Trickovic, Senior Vice President of Tintri said:“This launch represents a major milestone in our commitment to providing intelligent, autonomous infrastructure. We’re giving customers the exact tools they need to conquer the complexities of modern AI and edge computing, all while driving down operational costs.”

Hashtag: #Tintri #Platform9

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/tintri-and-platform9-announce-joint-solution-for-containerized-and-hypervisor-based-workloads/

Posted on

NZ-AU: Innovation Beverage Group Ltd. Announces Acquisition of Controlling Interest in BlockFuel Energy Inc. and Execution of Amended Merger Agreement

Source: GlobeNewswire (MIL-NZ-AU)

IBG Acquires 51% stake in BlockFuel Energy as business combination nears completion

Once complete, the combined entity will become a rising oil producer and power generation company with near-term production and scalable growth strategy

SYDNEY, March 25, 2026 (GLOBE NEWSWIRE) — Innovation Beverage Group Ltd (“IBG” or the “Company”) (Nasdaq: IBG), an innovative developer, manufacturer, and marketer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands, today announced that it has acquired a controlling interest in BlockFuel Energy Inc. (“BFE”), a Texas-based energy corporation. This transaction represents a significant milestone towards the proposed merger between both companies, which they anticipate closing in the coming weeks.

On March 16, 2026, IBG entered into a Share Exchange Agreement with certain shareholders of BFE pursuant to which IBG acquired 127,628 shares of BFE common stock, representing approximately 51% of BFE’s outstanding equity. As consideration for those shares, IBG issued warrants to purchase an aggregate of 3,815,766 ordinary shares of IBG at an exercise price of $0.0001 per share, which are not exercisable until shareholder approval and approval by The Nasdaq Stock Market LLC are obtained. The warrant shares represent 45.9% of the issued and outstanding shares of IBG and will represent 51% of the Merger Consideration payable at the time of the closing of the merger. Upon the consummation of the proposed merger between IBG and BFE, the warrants will be automatically adjusted to an aggregate of 20,643,297 ordinary shares of IBG and will be deemed exercised.

As part of the transaction, IBG also provided BFE with a $2.5 million unsecured loan, which facilitated the repurchase and cancellation of certain outstanding BFE shares. Following the closing of the previously announced merger, this loan will convert into an intercompany balance within the combined organization, further consolidating IBG’s ownership position.

Concurrently, IBG, BFE, and IBG’s wholly owned subsidiary, InnoBev Merger Corp., entered into an Amended and Restated Agreement and Plan of Merger. Upon completion of the proposed merger, BFE will become a wholly owned subsidiary of IBG and BFE equity holders are expected to own approximately 90% of the combined company, with IBG’s existing shareholders owning approximately 10%, subject to customary adjustments and dilution.

Strategic Transformation Nearing Completion

The transaction represents a strategic expansion of IBG into the energy and high-powered computing sectors. BFE focuses on the acquisition and development of oil and gas assets and the conversion of underutilized natural gas into electricity to power high-performance computing operations. BFE operates primarily in the United States, including Oklahoma, and is developing a vertically integrated platform combining energy production, power generation, and data centers.

Upon completion of the merger, the combined company is expected to operate under the BlockFuel Energy name, with IBG’s existing beverage business transitioning into an Australian-based subsidiary led by IBG’s CEO Sahil Beri as President. The new parent company will focus on scaling its U.S. onshore oil and gas operations.

“Completing the acquisition of a controlling interest in BlockFuel Energy advances our strategic transition and brings the merger closer to completion,” said Sahil Beri, Chief Executive Officer of Innovation Beverage Group. “We are positioning IBG for long-term growth by focusing on energy assets with strong fundamentals and near-term production potential, while maintaining our beverage business as a distinct subsidiary.”

“This transaction marks a significant step in building a scalable, U.S.-focused energy platform,” said Daniel Lanskey, Chief Executive Officer of BlockFuel Energy. “With a strengthened capital structure and aligned ownership, we are focused on advancing production and expanding our asset base as we begin operations.”

Building a Scalable U.S. Energy Platform

BlockFuel Energy is focused on the acquisition, development, and operation of oil and gas assets, with current operations primarily located in the United States, including acreage positions in Oklahoma.

The transaction provides IBG with immediate exposure to producing and development-stage energy assets, positioning the Company to pursue near-term revenue generation and long-term asset growth.

Based on preliminary engineering and comparable field deployments, BFE management believes onsite gas-to-power costs could be meaningfully below grid-based power pricing, while avoiding transportation, processing, and third-party power costs.

The acquisition was completed in connection with an amended and restated merger agreement between IBG and BFE. The closing of the full merger remains subject to customary conditions, including regulatory approvals and approval by The Nasdaq Stock Market LLC.

About Innovation Beverage Group Ltd

Innovation Beverage Group is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands for which it owns exclusive manufacturing rights. Focused on premium and super premium brands and market categories where it can disrupt age old brands, IBG’s brands include Australian Bitters, BITTERTALES, Drummerboy Spirits, Twisted Shaker, and more. IBG’s most successful brand to date is Australian Bitters, which is a well-established and favored bitters brand in Australia. Established in 2018, IBG’s headquarters, manufacturing and flavor innovation center are located in Sydney, Australia with a U.S. sales office located in California. For more information visit: https://www.innovationbev.com/.

About BlockFuel Energy

BlockFuel Energy is involved in the acquisition, exploration and development of proven oil fields onshore in North America. BlockFuel Energy combines state-of-the-art power generation with oil and gas exploration to power high-performance data centers. Our vertically integrated concept allows us to use co-location and modular power generation techniques to optimize efficiency and investment returns. Our cutting-edge solutions for energy optimization and extraction will enable us to transform underdeveloped resources into high-margin, scalable, and sustainable revenue streams. For more information visit: https://blockfuelenergy.com/.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the proposed merger between IBG and BlockFuel Energy, anticipated operational milestones, expected production levels, anticipated oil and gas sales, planned financing activities, expected economic benefits of such activities, and the proposed acquisition of additional oil field assets.

Forward-looking statements are typically identified by words such as “expects,” “anticipates,” “plans,” “projects,” “intends,” “believes,” “may,” “will,” “could,” “should,” or similar expressions. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, the ability of the parties to execute definitive transaction documents, satisfy closing conditions, obtain regulatory and stockholder approvals, commodity price volatility, operational risks, financing risks, , and other risks described in IBG’s filings with the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements. Neither IBG nor BFE undertakes any obligation to update such statements except as required by law.

Contact:

Innovation Beverage Group Limited
Sahil Beri
CEO
sahil@innovationbev.com
www.innovationbev.com

BlockFuel Energy Inc.
Daniel Lanskey
President and CEO
dan.lanskey@blockfuelenergy.com
www.blockfuelenergy.com

Investor Relations:

KCSA Strategic Communications
Phil Carlson, Managing Director
BlockFuel@KCSA.com

– Published by The MIL Network

LiveNews: https://livenews.co.nz/2026/03/26/nz-au-innovation-beverage-group-ltd-announces-acquisition-of-controlling-interest-in-blockfuel-energy-inc-and-execution-of-amended-merger-agreement/

Posted on

Strong Growth Prospects For European in Singapore’s Food Evolution

Source: Media Outreach

European Beef continues to grow in popularity in Singapore and is becoming one of the most sought-after products among consumers in the Asian country

SINGAPORE – Media OutReach Newswire – 25 March 2026 – In November 2025, Singapore adjusted its food security strategy, moving away from its “30 by 30” self-sufficiency target. This shift emphasizes global sourcing and strategic partnerships, creating an interesting opportunity for high-quality imports, including European beef from Spain.

Singapore’s shift towards a diversified and resilient food supply system underscores the importance of reliable imports. As Singapore improves its food security strategy, it also meets the growing demands of its sophisticated food scene, which highly values premium ingredients such as European beef.

The reason why European beef is the perfect choice.
Premium European beef is renowned for its exceptional flavor, while meeting the highest standards of safety, sustainability, traceability, and quality, in line with the European production model.

This makes it the perfect choice for the growing demand for high-quality meat in Singapore. As Singaporean diners increasingly seek unique experiences with premium beef, European beef offers a superior option, perfectly suited for fine dining restaurants and premium steakhouses, It is highly prized for its excellent qualities, such as its natural flavour, premium meat and superb texture.

With Singapore’s focus on diverse food sourcing, demand for high-quality beef is on the rise. The policy shift opens the door for European beef to flourish, especially in restaurants and food outlets that prioritize quality, taste, and sustainability.

European beef continues to grow in popularity in Singapore and is becoming one of the most sought-after products among consumers in the Asian country.

As Singapore strengthens its global food network, European beef is poised to become one of the preferred choices in the local market. The growing demand for sustainable, premium beef offers a significant opportunity for European beef to thrive in Singapore’s dynamic culinary landscape.

‘It’s time for European Beef in Singapore’.

Hashtag: #EuropeanBeef

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/26/strong-growth-prospects-for-european-in-singapores-food-evolution/

Posted on

Approaching.ai Brings in Top Scientists to Capture AI’s Inference Boom

Source: Media Outreach

BEIJING, CHINA – Media OutReach Newswire – 25 March 2026 – Approaching.ai has announced the appointment of two leading figures in computer science to accelerate its growth in high-efficiency AI infrastructure. Academician Wei-Min Zheng has joined as Chief Scientific Advisor, and Professor Yongwei Wu has been appointed Chief Scientist.

This move strengthens the company’s technical leadership and reinforces its long-term competitive moat in AI inference and Token production.

World-Class Expertise Reinforcing Technical Moat

Academician Wei-Min Zheng is a globally recognized authority in high-performance computing, distributed systems, and AI. His work on scalable storage architectures and parallel systems has had significant academic and industrial impact, earning multiple national science and technology awards.

Professor Yongwei Wu, an IEEE Fellow and AAIA Fellow, is an internationally recognized expert in parallel and distributed systems, cloud storage, and big data infrastructure, with multiple prestigious awards.

Their addition significantly enhances Approaching.ai’s ability to drive system-level innovation in large-scale AI inference—an area increasingly viewed as the core value layer of the AI industry.

Capturing the Core Value Layer: Inference and Token Production

As large models scale globally, demand for AI Tokens is growing exponentially. Inference is rapidly becoming the primary cost center and a key determinant of commercial viability.

Approaching.ai focuses on high-efficiency AI Token production, improving Token output per unit of compute and reducing deployment costs for enterprises.

Through system-level innovation, the company addresses key industry challenges:

  1. Fragmented computing resources
  2. Low inference efficiency
  3. Lack of standardized infrastructure

Its technologies—such as heterogeneous computing coordination and memory-compute optimization—enable unified execution across diverse hardware and models, creating a scalable and cost-efficient inference layer.

Strong Origin and Execution Capability

Originating from Tsinghua University’s High-Performance Computing Institute, Approaching.ai brings over 20 years of expertise in computing and storage systems, along with proven capability in translating research into industrial deployment.

Capital Validation and Market Confidence

Approaching.ai has attracted strong backing from leading venture capital firms and strategic investors, including GL Ventures, Verity Ventures, Shanghai Guofang Innovation Private Equity Fund Partnership (Limited Partnership), Xinglian Capital, Shangshi Capital, Tsinghua Capital, and other industry partners.

This reflects strong market confidence in the company’s positioning within the rapidly growing AI infrastructure market, particularly in inference optimization.

Looking Ahead

With strengthened scientific leadership, Approaching.ai will continue advancing enterprise-grade inference solutions and scalable AI infrastructure.

By focusing on Token production, the company targets one of the highest-leverage segments in the AI value chain and is well positioned to benefit from continued growth in AI adoption.

Hashtag: #AI

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

LiveNews: https://livenews.co.nz/2026/03/25/approaching-ai-brings-in-top-scientists-to-capture-ais-inference-boom/